| Ruth Tamrat, MD | |
|
2041 Georgia Ave Nw, 6th Floor, Huh Heart Center, Washington, DC 20060-2109 | |
| (202) 865-6679 | |
| Not Available |
| Full Name | Ruth Tamrat |
|---|---|
| Gender | Female |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 10 Years |
| Location | 2041 Georgia Ave Nw, Washington, District Of Columbia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952641094 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Howard University Hospital | Washington, DC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Howard University | 0941109565 | 136 |
News Archive
"The biggest culprit in Texas' growing debate over escalating Medicaid costs" is "[a] mathematical formula that calculates how much the federal government pays and what's left over for the state," Kaiser Health News, in collaboration with The Texas Tribune, reports. "Already facing a record budget shortfall, Texas' Federal Medical Assistance Percentage (FMAP) will drop more than 2 percentage points in late 2011, equivalent to a $1.2 billion hit."
The Canadian Breast Cancer Foundation is pleased to commend the 'Bust a Move' for Breast Health event to be held on January 30, 2010 at the Halifax Metro Centre. Hundreds of Canadians are expected to unite for this unique event to raise funds and awareness for the breast cancer cause, hosted by the QEII and IWK Foundations.
Alere, a global leader in rapid diagnostics, today doubled its commitment to the Organisation of African First Ladies Against HIV/AIDS in its efforts to reduce the impact of HIV/AIDS in Africa by eliminating mother-to-child transmission of HIV and increasing early infant diagnosis (EID).
Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, and the Multiple Myeloma Research Consortium announced today the initiation of a Phase II clinical trial of the cyclin-dependent kinase inhibitor, AT7519, to treat patients with relapsed or refractory multiple myeloma, an incurable blood cancer. The trial is designed to investigate both single agent and combination activity of AT7519 with bortezomib (Velcade®).
› Verified 9 days ago
| Entity Name | Howard University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033163597 PECOS PAC ID: 0941109565 Enrollment ID: O20040102000561 |
News Archive
"The biggest culprit in Texas' growing debate over escalating Medicaid costs" is "[a] mathematical formula that calculates how much the federal government pays and what's left over for the state," Kaiser Health News, in collaboration with The Texas Tribune, reports. "Already facing a record budget shortfall, Texas' Federal Medical Assistance Percentage (FMAP) will drop more than 2 percentage points in late 2011, equivalent to a $1.2 billion hit."
The Canadian Breast Cancer Foundation is pleased to commend the 'Bust a Move' for Breast Health event to be held on January 30, 2010 at the Halifax Metro Centre. Hundreds of Canadians are expected to unite for this unique event to raise funds and awareness for the breast cancer cause, hosted by the QEII and IWK Foundations.
Alere, a global leader in rapid diagnostics, today doubled its commitment to the Organisation of African First Ladies Against HIV/AIDS in its efforts to reduce the impact of HIV/AIDS in Africa by eliminating mother-to-child transmission of HIV and increasing early infant diagnosis (EID).
Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, and the Multiple Myeloma Research Consortium announced today the initiation of a Phase II clinical trial of the cyclin-dependent kinase inhibitor, AT7519, to treat patients with relapsed or refractory multiple myeloma, an incurable blood cancer. The trial is designed to investigate both single agent and combination activity of AT7519 with bortezomib (Velcade®).
› Verified 9 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952461816 PECOS PAC ID: 3779495858 Enrollment ID: O20040105000308 |
News Archive
"The biggest culprit in Texas' growing debate over escalating Medicaid costs" is "[a] mathematical formula that calculates how much the federal government pays and what's left over for the state," Kaiser Health News, in collaboration with The Texas Tribune, reports. "Already facing a record budget shortfall, Texas' Federal Medical Assistance Percentage (FMAP) will drop more than 2 percentage points in late 2011, equivalent to a $1.2 billion hit."
The Canadian Breast Cancer Foundation is pleased to commend the 'Bust a Move' for Breast Health event to be held on January 30, 2010 at the Halifax Metro Centre. Hundreds of Canadians are expected to unite for this unique event to raise funds and awareness for the breast cancer cause, hosted by the QEII and IWK Foundations.
Alere, a global leader in rapid diagnostics, today doubled its commitment to the Organisation of African First Ladies Against HIV/AIDS in its efforts to reduce the impact of HIV/AIDS in Africa by eliminating mother-to-child transmission of HIV and increasing early infant diagnosis (EID).
Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, and the Multiple Myeloma Research Consortium announced today the initiation of a Phase II clinical trial of the cyclin-dependent kinase inhibitor, AT7519, to treat patients with relapsed or refractory multiple myeloma, an incurable blood cancer. The trial is designed to investigate both single agent and combination activity of AT7519 with bortezomib (Velcade®).
› Verified 9 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1578638425 PECOS PAC ID: 3779495858 Enrollment ID: O20040805001280 |
News Archive
"The biggest culprit in Texas' growing debate over escalating Medicaid costs" is "[a] mathematical formula that calculates how much the federal government pays and what's left over for the state," Kaiser Health News, in collaboration with The Texas Tribune, reports. "Already facing a record budget shortfall, Texas' Federal Medical Assistance Percentage (FMAP) will drop more than 2 percentage points in late 2011, equivalent to a $1.2 billion hit."
The Canadian Breast Cancer Foundation is pleased to commend the 'Bust a Move' for Breast Health event to be held on January 30, 2010 at the Halifax Metro Centre. Hundreds of Canadians are expected to unite for this unique event to raise funds and awareness for the breast cancer cause, hosted by the QEII and IWK Foundations.
Alere, a global leader in rapid diagnostics, today doubled its commitment to the Organisation of African First Ladies Against HIV/AIDS in its efforts to reduce the impact of HIV/AIDS in Africa by eliminating mother-to-child transmission of HIV and increasing early infant diagnosis (EID).
Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, and the Multiple Myeloma Research Consortium announced today the initiation of a Phase II clinical trial of the cyclin-dependent kinase inhibitor, AT7519, to treat patients with relapsed or refractory multiple myeloma, an incurable blood cancer. The trial is designed to investigate both single agent and combination activity of AT7519 with bortezomib (Velcade®).
› Verified 9 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1073678637 PECOS PAC ID: 3779495858 Enrollment ID: O20100729000796 |
News Archive
"The biggest culprit in Texas' growing debate over escalating Medicaid costs" is "[a] mathematical formula that calculates how much the federal government pays and what's left over for the state," Kaiser Health News, in collaboration with The Texas Tribune, reports. "Already facing a record budget shortfall, Texas' Federal Medical Assistance Percentage (FMAP) will drop more than 2 percentage points in late 2011, equivalent to a $1.2 billion hit."
The Canadian Breast Cancer Foundation is pleased to commend the 'Bust a Move' for Breast Health event to be held on January 30, 2010 at the Halifax Metro Centre. Hundreds of Canadians are expected to unite for this unique event to raise funds and awareness for the breast cancer cause, hosted by the QEII and IWK Foundations.
Alere, a global leader in rapid diagnostics, today doubled its commitment to the Organisation of African First Ladies Against HIV/AIDS in its efforts to reduce the impact of HIV/AIDS in Africa by eliminating mother-to-child transmission of HIV and increasing early infant diagnosis (EID).
Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, and the Multiple Myeloma Research Consortium announced today the initiation of a Phase II clinical trial of the cyclin-dependent kinase inhibitor, AT7519, to treat patients with relapsed or refractory multiple myeloma, an incurable blood cancer. The trial is designed to investigate both single agent and combination activity of AT7519 with bortezomib (Velcade®).
› Verified 9 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1366781700 PECOS PAC ID: 3779495858 Enrollment ID: O20130507000207 |
News Archive
"The biggest culprit in Texas' growing debate over escalating Medicaid costs" is "[a] mathematical formula that calculates how much the federal government pays and what's left over for the state," Kaiser Health News, in collaboration with The Texas Tribune, reports. "Already facing a record budget shortfall, Texas' Federal Medical Assistance Percentage (FMAP) will drop more than 2 percentage points in late 2011, equivalent to a $1.2 billion hit."
The Canadian Breast Cancer Foundation is pleased to commend the 'Bust a Move' for Breast Health event to be held on January 30, 2010 at the Halifax Metro Centre. Hundreds of Canadians are expected to unite for this unique event to raise funds and awareness for the breast cancer cause, hosted by the QEII and IWK Foundations.
Alere, a global leader in rapid diagnostics, today doubled its commitment to the Organisation of African First Ladies Against HIV/AIDS in its efforts to reduce the impact of HIV/AIDS in Africa by eliminating mother-to-child transmission of HIV and increasing early infant diagnosis (EID).
Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, and the Multiple Myeloma Research Consortium announced today the initiation of a Phase II clinical trial of the cyclin-dependent kinase inhibitor, AT7519, to treat patients with relapsed or refractory multiple myeloma, an incurable blood cancer. The trial is designed to investigate both single agent and combination activity of AT7519 with bortezomib (Velcade®).
› Verified 9 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1497023188 PECOS PAC ID: 3779495858 Enrollment ID: O20131029000108 |
News Archive
"The biggest culprit in Texas' growing debate over escalating Medicaid costs" is "[a] mathematical formula that calculates how much the federal government pays and what's left over for the state," Kaiser Health News, in collaboration with The Texas Tribune, reports. "Already facing a record budget shortfall, Texas' Federal Medical Assistance Percentage (FMAP) will drop more than 2 percentage points in late 2011, equivalent to a $1.2 billion hit."
The Canadian Breast Cancer Foundation is pleased to commend the 'Bust a Move' for Breast Health event to be held on January 30, 2010 at the Halifax Metro Centre. Hundreds of Canadians are expected to unite for this unique event to raise funds and awareness for the breast cancer cause, hosted by the QEII and IWK Foundations.
Alere, a global leader in rapid diagnostics, today doubled its commitment to the Organisation of African First Ladies Against HIV/AIDS in its efforts to reduce the impact of HIV/AIDS in Africa by eliminating mother-to-child transmission of HIV and increasing early infant diagnosis (EID).
Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, and the Multiple Myeloma Research Consortium announced today the initiation of a Phase II clinical trial of the cyclin-dependent kinase inhibitor, AT7519, to treat patients with relapsed or refractory multiple myeloma, an incurable blood cancer. The trial is designed to investigate both single agent and combination activity of AT7519 with bortezomib (Velcade®).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ruth Tamrat, MD 2041 Georgia Ave Nw Ste 3400, Washington, DC 20060-0001 Ph: (202) 215-5979 | Ruth Tamrat, MD 2041 Georgia Ave Nw, 6th Floor, Huh Heart Center, Washington, DC 20060-2109 Ph: (202) 865-6679 |
News Archive
"The biggest culprit in Texas' growing debate over escalating Medicaid costs" is "[a] mathematical formula that calculates how much the federal government pays and what's left over for the state," Kaiser Health News, in collaboration with The Texas Tribune, reports. "Already facing a record budget shortfall, Texas' Federal Medical Assistance Percentage (FMAP) will drop more than 2 percentage points in late 2011, equivalent to a $1.2 billion hit."
The Canadian Breast Cancer Foundation is pleased to commend the 'Bust a Move' for Breast Health event to be held on January 30, 2010 at the Halifax Metro Centre. Hundreds of Canadians are expected to unite for this unique event to raise funds and awareness for the breast cancer cause, hosted by the QEII and IWK Foundations.
Alere, a global leader in rapid diagnostics, today doubled its commitment to the Organisation of African First Ladies Against HIV/AIDS in its efforts to reduce the impact of HIV/AIDS in Africa by eliminating mother-to-child transmission of HIV and increasing early infant diagnosis (EID).
Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, and the Multiple Myeloma Research Consortium announced today the initiation of a Phase II clinical trial of the cyclin-dependent kinase inhibitor, AT7519, to treat patients with relapsed or refractory multiple myeloma, an incurable blood cancer. The trial is designed to investigate both single agent and combination activity of AT7519 with bortezomib (Velcade®).
› Verified 9 days ago
Dr. Adefolaju Oketokun, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1629 K Street Nw, Suite 300, Washington, DC 20006 Phone: 202-636-1360 Fax: 202-636-5137 | |
Dr. Uzoamaka Theodora Nwaogwugwu, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2041 Georgia Avenue Nw, Washington, DC 20060 Phone: 202-865-7677 | |
Ms. Sruthi Nukalapati Reddy, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3800 Reservoir Road Nw, 6 Phc, Washington, DC 20007 Phone: 202-444-8123 | |
Dr. Kaustubh Subhash Yadwadkar, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3800 Reservoir Rd Nw, Cg201, Washington, DC 20007 Phone: 304-206-7595 | |
Dr. Monica Vohra, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1525 7th St Nw, Washington, DC 20001 Phone: 202-386-7020 Fax: 202-265-1970 | |
Anteneh A Tesfaye, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 110 Irving St Nw Ste C2151, Washington, DC 20010 Phone: 202-877-6998 Fax: 202-877-8909 | |
Erica Nakajima, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5255 Loughboro Rd Nw Fl 1, Washington, DC 20016 Phone: 202-660-6500 |